logo
logo
Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

NASDAQ•GLUE
CEO: Dr. Markus Warmuth M.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2021-06-24
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
連絡先情報
321 Harrison Avenue, Suite 900, Boston, MA, 02118, United States
617-949-2643
www.monterosatx.com
時価総額
$1.17B
PER (TTM)
70.5
34.3
配当利回り
--
52週高値
$25.77
52週安値
$3.50
52週レンジ
65%
順位61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$12.77M+38.54%
直近4四半期の推移

EPS

-$0.33+13.79%
直近4四半期の推移

フリーCF

$99.78M-566.40%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Collaboration Revenue Soars Nine-month collaboration revenue reached $120.9M, up $105.9M, driven by Roche and Novartis agreements.
Nine-Month Profitability Achieved Swung to $7.5M net income for nine months, reversing prior year's $86.1M net loss.
Major Novartis Deal Closed Received $120.0M upfront payment from September 2025 Novartis deal, supporting future development.
Strong Liquidity Position Cash, cash equivalents, and marketable securities totaled $396.2M, supporting operations for at least twelve months.

リスク要因

Continued Operating Losses Expected Expect continued significant operating losses and negative cash flows as product development continues indefinitely.
High R&D Spending Increases Nine-month R&D expenses rose $16.8M to $99.5M, driven by clinical trial advancements and pipeline progression.
Future Financing Uncertainty Additional funding is necessary for future research; success in raising capital on acceptable terms is not assured.
Clinical Trial Execution Risk Successful development and regulatory approval of product candidates remain highly uncertain, costly, and time-consuming endeavors.

見通し

MRT-8102 Trial Results Due Initial safety and tolerability results from MRT-8102 Phase 1 study anticipated in the first half of 2026.
Novartis Collaboration Advancement Applying proprietary QuEEN™ engine for discovery/development of degraders under the new September 2025 agreement.
Funding Runway Confirmed Existing cash resources expected to fund operating expenses and capital needs for at least the next twelve months.
Deferred Revenue Recognition Remaining deferred revenue from Novartis agreements expected to be recognized over the next 36 to 60 months.

同業比較

売上高 (TTM)

Arvinas, Inc.ARVN
$312.30M
+93.9%
Keros Therapeutics, Inc.KROS
$246.72M
+37798.3%
Valneva SEVALN
$198.55M
+13.5%

粗利益率 (最新四半期)

Arvinas, Inc.ARVN
100.0%
+0.0pp
Astria Therapeutics, Inc.ATXS
100.0%
+0.0pp
Keros Therapeutics, Inc.KROS
97.2%
+78.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ERAS$3.72B-26.7-33.1%11.5%
NRIX$1.35B-5.6-57.5%8.1%
KOD$1.17B-5.4-246.2%28.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-40.5%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月19日
|
EPS:-$0.45
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $12.77M+38.5%
    |
    EPS: $-0.33+13.8%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $23.19M+394.0%
    |
    EPS: $-0.15-65.1%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $84.93M+7882.0%
    |
    EPS: $0.57-207.5%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月20日|
    売上高: $75.62M+0.0%
    |
    EPS: $-0.98+62.7%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $9.22M+0.0%
    |
    EPS: $-0.29-58.6%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $4.70M+0.0%
    |
    EPS: $-0.43-39.4%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月9日|
    売上高: $1.06M+0.0%
    |
    EPS: $-0.53-11.7%
    予想通り

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月14日|
    売上高: $0.00+0.0%
    |
    EPS: $-2.63-14.3%
    不明